Chris H. Takimoto

Expression of Epiregulin and Amphiregulin and <i>K-ras</i> Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated With Cetuximab

Shirin Khambata‐Ford, Christopher R. Garrett, Neal J. Meropol et al. · Journal of Clinical Oncology · 2007 · 1.1K citations · Full text

Medicine, Genetics, Oncology +17

CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin’s Lymphoma

Ranjana H. Advani, Ian W. Flinn, Leslie Popplewell et al. · New England Journal of Medicine · 2018 · 1.1K citations · Full text

Life Sciences, Immunology, Oncology +17

Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies

Manuel Hidalgo, Lillian L. Siu, John Nemunaitis et al. · Journal of Clinical Oncology · 2001 · 1K citations

Medicine, Oncology, Pharmacology +15

First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers

Branimir I. Šikić, Nehal J. Lakhani, Amita Patnaik et al. · Journal of Clinical Oncology · 2019 · 590 citations · Full text

Pharmacy, Oncology, Pharmacology +17

Phase II Study of Sorafenib in Patients With Metastatic or Recurrent Sarcomas

Robert G. Maki, David R. D’Adamo, Mary Louise Keohan et al. · Journal of Clinical Oncology · 2009 · 573 citations · Full text

Medicine, Oncology, Cancer Pharmacology +15